Search Results
Your search for all items matches 36703 pages
Showing 1 - 50Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer
On July 14, the U.S. Food and Drug Administration (FDA) approved gedatolisib (Revtorpyk) in combination with fulvestrant, with or without palbociclib, for the treatment of adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA...
Wassim McHayleh, MD, FACP, MBA, on Elacestrant Plus Capivasertib in ER-Positive/HER2-Negative Advanced Breast Cancer: Update From ELEVATE
Wassim McHayleh, MD, FACP, MBA, of AdventHealth Cancer Institute, provides an update from the phase Ib/II ELEVATE trial, an open-label umbrella study. This report focuses on updated safety and preliminary efficacy for elacestrant and capivasertib for patients with estrogen receptor...
FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors
On July 14, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo), an oral RET inhibitor, for adult and pediatric patients aged 2 years and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved...
Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors
Setmelanotide significantly reduced body mass index (BMI) and signs of hunger in patients with acquired hypothalamic obesity, according to findings from the phase III TRANSCEND trial published in The New England Journal of Medicine. “Our findings represent a major breakthrough for children and...
Radiotherapy Dose Escalation With Intraoperative Radiotherapy vs Surgery Alone in Glioblastoma
In a phase III trial (INTRAGO-II) reported in The Lancet Oncology, Giordano et al found that the addition of intraoperative radiotherapy to surgery did not improve outcomes in patients with newly diagnosed glioblastoma. Study Details The open-label trial enrolled 298 patients (full-analysis set)...
Stage III HER2-Negative Breast Cancer With HRD: Standard Chemotherapy Plus Olaparib
In a European phase III trial (SUBITO) reported in The Lancet Oncology, Seefat et al found that intensified alkylating chemotherapy with autologous stem cell rescue (IACT) provided no overall survival advantage vs standard chemotherapy followed by olaparib in patients with stage IIIA-C...
American Cancer Society Reports Latest Global Cancer Statistics
New findings in a report led by the American Cancer Society (ACS) reveal an urgent picture of a growing global cancer burden and underscore the life-saving potential of stronger prevention and equitable access to care. According to Global Cancer Statistics, 2026, nearly 21 million people were...
Emergency Hospital Admission Accounts for 40% of Ovarian Cancer Diagnoses in England
About two in five women diagnosed with ovarian cancer were only diagnosed after an emergency admission to the hospital, according to the results of a national population-based study from England that was published in BMJ Oncology. “The risk of being diagnosed with ovarian cancer after an emergency ...
Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal-Only Metastases
In a phase III trial (CAIRO6) reported in The Lancet Oncology, Rovers et al found that perioperative systemic therapy was not associated with significant improvement in overall survival vs surgery alone in patients with resectable peritoneal-only metastases of colorectal adenocarcinoma. Study...
Breast Cancer: Tailoring Radiotherapy Based on Nodal Response to Primary Chemotherapy
As reported in The Lancet Oncology by Mauritz et al, 10-year follow-up of a Dutch prospective registry study (RAPCHEM: BOOG 2010–03) indicated that tailoring postoperative locoregional radiotherapy based on nodal response to primary chemotherapy was associated with maintenance of a low locoregional ...
Shared Risk Factors Between Breast Cancer and Atrial Fibrillation/Flutter
Alcohol use and smoking were linked to breast cancer and atrial fibrillation/flutter in women aged 55 years and older in multiple regions of the world, according to new research published by Zhang et al in the Journal of the American Heart Association. Breast cancer and atrial fibrillation—also...
FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer
On July 10, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex), each in combination with the NECTIN4-directed antibody-drug conjugate enfortumab vedotin-ejfv (Padcev), as neoadjuvant...
FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
On July 9, the U.S. Food and Drug Administration (FDA) approved the anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications. The specific indications approved for isatuximab are: In combination with pomalidomide and dexamethasone...
Long-Term Overall Survival With Addition of SBRT to Abiraterone Acetate and ADT in Oligometastatic Castration-Resistant Prostate Cancer
As reported in The Lancet Oncology by Francolini et al, an unplanned long-term analysis of overall survival in the Italian phase II ARTO trial showed a survival benefit with the addition of metastasis-directed therapy with stereotactic body radiotherapy (SBRT) to abiraterone acetate and...
Head and Neck Cancer: Long-Term Follow-up of Postoperative Chemoradiotherapy With 3-Weekly vs Weekly Cisplatin
In the long-term follow-up of a Japanese phase II/III trial (JCOG1008) reported in the Journal of Clinical Oncology, Tahara et al found maintained noninferiority of chemoradiotherapy with weekly vs every-3-week cisplatin for overall survival in patients with postoperative high-risk locally advanced ...
Advanced Gastric or GEJ Cancer: First-Line Disitamab Vedotin, Tislelizumab, and S-1
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Li et al found that the first-line combination of disitamab vedotin, tislelizumab, and S-1 was associated with high activity in patients with HER2-overexpressing advance gastric/gastroesophageal junction (GEJ) ...
Case 3: Metastatic Hepatocellular Carcinoma After Failure of First-Line Immunotherapy
This is Part 3 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss management of...
Case 2: Metastatic Hepatocellular Carcinoma
This is Part 2 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss the management of...
Case 1: Liver-Limited Hepatocellular Carcinoma
This is Part 1 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss treatment...
Oral Cancer: Novel Diagnostic Test Demonstrates High Accuracy
A noninvasive oral brush biopsy test adapted from a molecular assay was able to quickly distinguish oral squamous cell carcinoma from other oral disorders with high accuracy, according to results from a large diagnostic case-control study published in Biomarker Research. “Oral cancer survival is...
In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types
Between 2015 and 2022, men were more likely than women to be diagnosed with regional and/or distant stages of 20 nonreproductive solid cancer types in the United States, according to a study published by Maclin et al in Cancer Epidemiology, Biomarkers & Prevention. The study’s findings may...
Targeting BCL2 May Overcome Acquired Resistance in BRAF-Mutant Melanoma
Targeting BCL2 family proteins may counteract acquired resistance to BRAF and MEK inhibition in patients with BRAF-mutant metastatic melanoma, according to findings from a preclinical study published in Nature Communications. “Targeted therapy works by shutting down the main signal driving...
Case 3: Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
This is Part 3 of Integrating Immunotherapy Across the SCLC Spectrum, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Laura Alder, MD, Noura Choudhury, MD, and Alissa Cooper, MD, discuss second-line treatment of extensive-stage...
Case 2: De Novo Extensive-Stage Small Cell Lung Cancer
This is Part 2 of Integrating Immunotherapy Across the SCLC Spectrum, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Laura Alder, MD, Noura Choudhury, MD, and Alissa Cooper, MD, discuss the management of de novo extensive-stage...
Case 1: Limited-Stage Small Cell Lung Cancer
This is Part 1 of Integrating Immunotherapy Across the SCLC Spectrum, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Laura Alder, MD, Noura Choudhury, MD, and Alissa Cooper, MD, discuss the management of limited-stage small cell...
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
The addition of radiotherapy to the S-1 plus oxaliplatin (SOX) chemotherapy regimen did not improve disease-free or overall survival in patients with pathologic T4 and/or node-positive gastric adenocarcinoma who underwent D2 gastrectomy (ie, R0 resection with D2 lymphadenectomy), based on a phase...
Intraoperative Margin Assessment With Specimen PET/CT Imaging in Early Breast Cancer
In a European trial (BrIMA) reported in JAMA Surgery, Göker et al found that specimen PET/CT imaging was associated with improved detection of positive margins in surgery for early breast cancer. Study Details The study recruited patients from six European breast centers between June 2022 and March ...
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
In a single-center phase I to II trial (SAVE) reported in the Journal of Clinical Oncology, Issa et al found that the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax was highly active in patients with relapsed or refractory acute myeloid leukemia (AML). Revumenib is an...
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia called blastic plasmacytoid dendritic cell neoplasm (BPDCN) may eventually develop resistance to tagraxofusp-ezrs, the first U.S. Food and Drug Administration–approved...
Inotuzumab Ozogamicin Induces Long-Term Survival in B-Cell ALL
Inotuzumab ozogamicin was able to eliminate residual disease among adult patients with B-cell acute lymphoblastic leukemia (ALL), leading to improved long-term overall survival outcomes, according to findings from a single-center phase II trial published in Blood Cancer Journal. “Our results show...
Disparities in Cancer Screening Persist Among Sexual Orientation and Gender Identity Minority Populations
New research has uncovered persistent disparities in preventive cancer care across different sexual orientation and gender identity (SOGI) minority populations. The study—published by Arena et al in the journal Cancer—found particular concern for cervical and breast cancer screening. To assess SOGI ...
Zenocutuzumab Shows Durable Antitumor Activity in NRG1-Positive Cholangiocarcinoma
Zenocutuzumab induced clinically meaningful antitumor activity and showed a favorable safety profile in patients with advanced NRG1-positive cholangiocarcinoma, according to findings from the phase II eNRGy trial published in the Journal of Clinical Oncology. “Second-line chemotherapy is only...
Early Research Explores How Fatty Liver Disease May Affect Liver Metastasis Among Patients With Colorectal Cancer
Researchers have uncovered how fatty liver disease can fuel the most aggressive form of metastatic colorectal cancer. The findings, published by Peng-Winkler et al in Nature, not only explain why some patients face poorer outcomes but also highlight how metabolic conditions such as fatty liver...
Impact of Treatment Delays in Early-Onset Colorectal Cancer
In a retrospective, population-based, cross-sectional study reported in JAMA Oncology, Heslin et al found that treatment delay in early-onset colorectal cancer was associated with poorer overall survival. Study Details The study used Texas Cancer Registry data from patients diagnosed with...
Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
In the long-term follow-up to a phase II study published in The New England Journal of Medicine, Ruella et al found that a single infusion of the CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 (now called tisagenlecleucel) produced decade-long remissions in a subset of patients ...
AI-Powered Tumor Microenvironment Analysis May Predict Immunotherapy Response in Patients With Rare Cancers
Analysis of the tumor microenvironment before and during treatment with the help of artificial intelligence (AI) may aid in predicting response to pembrolizumab in patients with rare cancers, according to findings of a study published in the Journal for ImmunoTherapy of Cancer. “AI-based pathology ...
Study Clarifies HPV-Related Cancer Risk in Immunosuppressed Populations
As reported in JAMA Network Open by Meglic et al, a Swedish nested case-control study of immunosuppressed populations found that both people with human immunodeficiency virus (HIV) and solid organ transplant recipients had increased odds of human papillomavirus (HPV)–related cancers, although the...
Performance of Lung Cancer Risk Prediction Models Across Racial and Ethnic Groups in the United States
A new study led by scientists from the International Agency for Research on Cancer (IARC) compared the performance of lung cancer risk prediction models against the criteria currently used to determine eligibility for lung cancer screening in the United States. Reseatchers found that all the...
Study Uncovers How Obesity Influences Molecular Pathways in Breast Cancer Progression
A novel study has found that obesity is associated with a distinct molecular program driving the transition from early-stage, premalignant breast lesions to invasive breast cancer. Rather than simply showing increased activation of classical invasive pathways, tumors from patients with obesity...
Second Primary Malignancies After T-Cell–Engaging Bispecific Antibody Therapy
In a meta-analysis reported in JAMA Oncology, Tomasik et al found that second primary malignant neoplasms were a “clinically relevant complication” of treatment with T-cell–engaging bispecific antibodies (BsAbs) in patients with non-Hodgkin lymphoma or multiple myeloma. Study Details The analysis...
Previously Untreated Advanced NSCLC With High PD-L1 Expression: PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy?
In a meta-analysis reported in JAMA Oncology, Di Federico et al found that the addition of first-line platinum-based chemotherapy to PD-1/-L1 inhibition was associated with improved outcomes in patients with advanced non–small cell lung cancer (NSCLC) with high PD-L1 expression. Study Details The...
Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans
In a study reported in The Lancet Oncology, Kirby et al identified real-world heart and lung radiation doses associated with English National Health Service (NHS) radiotherapy treatment plans in breast radiotherapy practices. Study Details The study involved data from 26,236 eligible patients...
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, has announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research...
AACR Statement and Call to Action Concerning OMB Proposal
On June 30, the American Association for Cancer Research (AACR) issued the following statement: The American Association for Cancer Research (AACR) is deeply concerned that the recent action of the White House Office of Management and Budget (OMB) to propose a new set of regulations on how federal...
FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant
On June 30, the U.S. Food and Drug Administration (FDA) approved allogeneic regulatory T-cell–based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative...
Single-Fraction SBRT in Localized Prostate Cancer
In a phase I/II trial reported in JAMA Oncology, Zilli et al found that single-fraction high-dose stereotactic body radiotherapy (SBRT) was associated with a high biochemical relapse–free survival rate in patients with localized prostate cancer. Study Details In the trial, 43 patients with...
Case 3: Toxicity Management in ER-Positive Breast Cancer
This is Part 3 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Sara Tolaney, MD, MPH, FASCO, Erica...
Case 2: High-Risk ER-Positive Early Breast Cancer With Germline BRCA Mutation
This is Part 2 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Sara Tolaney, MD, MPH, FASCO, Erica...
Case 1: Understanding Risk of Recurrence in ER-Positive Early Breast Cancer
This is Part 1 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Sara Tolaney, MD, MPH, FASCO, Erica...
Antonio Llombart-Cussac, MD, PhD, on ADELA: Elacestrant Plus Everolimus in ESR1-Mutated ER-Positive HER2-Negative Advanced Breast Cancer
Antonio Llombart-Cussac, MD, PhD, of Medica Scientia Innovation Research (MEDSIR), discusses the ongoing ADELA study, a double-blind, placebo-controlled, randomized phase III trial of elacestrant plus everolimus vs elacestrant plus placebo in patients with estrogen receptor (ER)-positive...
